27 completed, 6 terminated, 3 unknown, 1 active not recruiting. 37 Phase 1, 14 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 37 | Completed 27, Terminated 6, Unknown 3, Active not recruiting 1 |
| Phase 2 | 14 | Completed 10, Terminated 2, Unknown 2 |
Follow Mitoxantrone Hydrochloride: new trials by email Literature Review of Mitoxantrone Hydrochloride trials Research Report on Mitoxantrone Hydrochloride
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Testing the Addition of an Anti-cancer Drug, M3814, to the Usual Treatment (Mitoxantrone, Etoposide, and Cytarabine) for Relapsed or Refractory Acute Myeloid Leukemia Biospecimen Collection, Bone Marrow Biopsy, Cytarabine - Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia | Phase 1 | Active not recruiting | National Cancer Institute (NCI) | 48 | 2020-05-05 | 2026-06-11 |
| Gemtuzumab Ozogamicin With G-CSF, Cladribine, Cytarabine & Mitoxantrone for Untreated AML & High-Grade Myeloid Neoplasm Cladribine, Cytarabine, Gemtuzumab Ozogamicin - Acute Myeloid Leukemia | Phase 1 / Phase 2 | Completed | Fred Hutchinson Cancer Center | 66 | 2018-09-14 | 2023-08-30 |
| Decitabine With GCLAM for Adults With Newly Diagnosed, Relapsed, or Refractory AML or High-Risk MDS Cladribine, Cytarabine, Decitabine - Mixed Phenotype Acute Leukemia, Previously Treated Myelodysplastic Syndrome | Phase 1 / Phase 2 | Completed | Fred Hutchinson Cancer Center | 28 | 2016-11-17 | 2020-03-17 |
| Selinexor With Combination Chemotherapy in Treating Patients With Acute Myeloid Leukemia Cytarabine, Mitoxantrone Hydrochloride, Selinexor - Acute Myeloid Leukemia | Phase 1 | Completed | University of Chicago | 25 | 2015-10-07 | 2020-04-08 |
| CPI-613, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Granulocytic Sarcoma 6,8-Bis(benzylthio)octanoic Acid, Cytarabine, Hematopoietic Cell Transplantation - Granulocytic Sarcoma, Recurrent Adult Acute Myeloid Leukemia | Phase 1 | Completed | Wake Forest University Health Sciences | 48 | 2015-09-01 | 2024-09-19 |
| Selinexor and Chemotherapy in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia mitoxantrone hydrochloride, etoposide, cytarabine - Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q) | Phase 1 | Completed | Alice Mims | 23 | 2015-05-18 | 2023-06-15 |
| Ixazomib, Mitoxantrone Hydrochloride, Etoposide, and Intermediate-Dose Cytarabine in Relapsed or Refractory Acute Myeloid Leukemia ixazomib, mitoxantrone hydrochloride, etoposide - Recurrent Adult Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia | Phase 1 | Completed | Case Comprehensive Cancer Center | 30 | 2014-10-08 | 2018-12-13 |
| Lenalidomide and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia lenalidomide, mitoxantrone hydrochloride, etoposide - Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Differentiated Myeloid Leukemia (M0) | Phase 1 | Terminated | Stanford University | 17 | 2014-02-01 | 2018-10-29 |
| Filgrastim, Cladribine, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With Newly Diagnosed or Relapsed/Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes Cladribine, Cytarabine, Filgrastim - Acute Biphenotypic Leukemia, de Novo Myelodysplastic Syndrome | Phase 1 / Phase 2 | Completed | Fred Hutchinson Cancer Center | 199 | 2014-01-23 | 2020-01-10 |
| Donor Stem Cell Transplant in Treating Patients With High Risk Acute Myeloid Leukemia mitoxantrone hydrochloride, cytarabine, peripheral blood stem cell transplantation - Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Monoblastic Leukemia (M5a) | Phase 1 | Terminated | University of Southern California | 10 | 2013-03-06 | 2018-03-30 |
| CPI-613, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia CPI-613, cytarabine, mitoxantrone hydrochloride - Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q) | Phase 1 | Completed | Wake Forest University Health Sciences | 67 | 2013-01-01 | 2018-07-03 |
| Decitabine Followed by Mitoxantrone Hydrochloride, Etoposide, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes Cytarabine, Decitabine, Etoposide - Previously Treated Myelodysplastic Syndrome, Recurrent Adult Acute Myeloid Leukemia | Phase 1 / Phase 2 | Completed | Fred Hutchinson Cancer Center | 52 | 2012-12-20 | 2019-02-07 |
| Azacitidine, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With High-Risk Acute Myeloid Leukemia azacitidine, cytarabine, mitoxantrone hydrochloride - Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Monoblastic Leukemia (M5a) | Phase 1 | Completed | University of Chicago | 50 | 2012-06-06 | 2020-05-15 |
| Temsirolimus, Dexamethasone, Mitoxantrone Hydrochloride, Vincristine Sulfate, and Pegaspargase in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Non-Hodgkin Lymphoma Dexamethasone, Laboratory Biomarker Analysis, Methotrexate - Childhood B Acute Lymphoblastic Leukemia, Childhood T Acute Lymphoblastic Leukemia | Phase 1 | Completed | National Cancer Institute (NCI) | 13 | 2011-09-01 | 2015-07-10 |
| Cyclosporine, Pravastatin Sodium, Etoposide, and Mitoxantrone Hydrochloride in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia cyclosporine, pravastatin sodium, mitoxantrone hydrochloride - Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Differentiated Myeloid Leukemia (M0) | Phase 1 / Phase 2 | Terminated | Fred Hutchinson Cancer Center | 6 | 2011-04-01 | 2017-07-02 |
| Azacitidine in Combination With Mitoxantrone, Etoposide Phosphate, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia Azacitidine, Cytarabine, Etoposide Phosphate - Recurrent Adult Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia | Phase 1 | Completed | National Cancer Institute (NCI) | 24 | 2011-01-20 | 2017-09-21 |
| Azacitidine, Mitoxantrone Hydrochloride, and Etoposide in Treating Older Patients With Poor-Prognosis Acute Myeloid Leukemia Azacitidine, Etoposide, Laboratory Biomarker Analysis - Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Adult Acute Basophilic Leukemia | Phase 1 | Terminated | National Cancer Institute (NCI) | 13 | 2010-12-01 | 2015-08-20 |
| Everolimus MICE-regimen in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia cytarabine, etoposide, everolimus - Leukemia | Phase 1 | Completed | Gruppo Italiano Malattie EMatologiche dell'Adulto | 11 | 2010-10-01 | 2022-10-26 |
| Phase I Combination of Midostaurin, Bortezomib, and Chemo in Relapsed/Refractory Acute Myeloid Leukemia midostaurin, Bortezomib, mitoxantrone hydrochloride - Acute Myeloid Leukemia, Acute Myeloid Leukemia With Multilineage Dysplasia Following | Phase 1 | Completed | Alison Walker | 34 | 2010-08-01 | 2016-07-06 |
| Bortezomib, Mitoxantrone, Etoposide, and Cytarabine in Relapsed or Refractory Acute Myeloid Leukemia bortezomib, mitoxantrone hydrochloride, etoposide - Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Differentiated Myeloid Leukemia (M0) | Phase 1 | Completed | Case Comprehensive Cancer Center | 3 | 2010-07-01 | 2015-08-13 |
Showing 20 of 37. Sign in to see all of them.
Leukemia, Myeloid, Acute (24) · Congenital Abnormalities (13) · Leukemia (10) · Leukemia, Erythroblastic, Acute (8) · Leukemia, Megakaryoblastic, Acute (8) · Leukemia, Monocytic, Acute (8) · Leukemia, Myelomonocytic, Acute (8) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (7) · Myelodysplastic Syndromes (3) · Prostatic Neoplasms (3) · Carcinoma, Ovarian Epithelial (2) · Leukemia, Basophilic, Acute (2) · Leukemia, Biphenotypic, Acute (2) · Leukemia, Eosinophilic, Acute (2) · Leukemia, Lymphocytic, Chronic, B-Cell (2)
Fred Hutchinson Cancer Center (8) · National Cancer Institute (NCI) (8) · Case Comprehensive Cancer Center (2) · University of Chicago (2) · Wake Forest University Health Sciences (2) · Alice Mims (1) · Alison Walker (1) · Children's Oncology Group (1) · Dartmouth-Hitchcock Medical Center (1) · Georgetown University (1) · Gruppo Italiano Malattie EMatologiche dell'Adulto (1) · Herbert Irving Comprehensive Cancer Center (1) · Hope Cancer Institute, Inc. (1) · Institut Paoli-Calmettes (1) · Lymphoma Trials Office (1)
United States (33) · Canada (4) · Australia (2) · France (1) · Italy (1) · United Kingdom (1)
Roland Walter (4) · Anjali Advani (2) · Judith Karp (2) · Alice Mims, MD (1) · Alison Walker (1) · Alison Walker, MD (1) · Andrea Harzstark (1) · Andrew D. Zelenetz, MD, PhD (1) · Ann Mohrbacher (1) · Anna Halpern (1) · Bayard Powell (1) · Brian A Jonas (1) · Christopher H. Lowrey, MD (1) · Daniel P. Petrylak, MD (1) · David F. Claxton, MD (1)
PMID 18299450, PMID 18467731, PMID 19349545, PMID 19638218, PMID 20071660, PMID 20209646, PMID 21239698, PMID 24048789, PMID 26784138, PMID 29304833, PMID 32074275, PMID 32077361, PMID 35354808, PMID 37665178
P30CA015704 (3), P30CA012197 (2), U01CA070095 (2), 2008 (1), N01CM00032 (1), N01CM62202 (1), N01CM62203 (1), P30CA014599 (1), P30CA016058 (1), P30CA023108 (1), P30CA043703 (1), P30CA051008 (1), P30CA124435 (1), U01CA062491 (1), U01CA069854 (1)